Shares in Fisher & Paykel Healthcare [NZX: FPH] are near a seven-year high as the maker of breathing masks and respirators continued an 18-month trend of "winning back favour" with investors, according to an analyst
The stock rose 3 percent to $4.09 today, and has steadily climbed 77 percent over the last two years, as it recovered from loss of market share, and a "stubbornly high" New Zealand dollar, Mark Lister head of private wealth research at Craigs Investment Partners told BusinessDesk. Because the Auckland based company exports most of its respiratory products, it is exposed to fluctuations in the currency.
The kiwi has "been high for three years now. It's sort of plateaued, it hasn't gone down, but it hasn't gone up either," Lister said. "If the kiwi dollar fell tomorrow Fisher & Paykel would go up," but investors were increasingly more focused on "what's going on in their offshore market."
The stock is rated an average 'hold' based on a consensus of seven analysts compiled by Reuters, though there's a divided view with four 'buy' ratings, two 'hold' and one 'strong sell'. The analysts' median target price is $4.10.
In November, F&P Healthcare said it expects annual profit of between $90 million and $95 million, though trimmed its predictions for operating revenue to a range of $610 million to $625 million from between $625 million and $645 million on a slightly stronger currency than anticipated.
Craigs' Lister said the company has mitigated the impact of the strong currency "by getting the right product cycle, getting the right products into the right markets at the right time."
This turnaround in their business has caused "investors to change their tune", especially as the market grew more comfortable with a high kiwi, Lister said.
"F&P is still growing in those offshore markets, even though there is a high dollar, they're still seeing growth, so they're able to weather the storm," he said.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- 'Real housewife' lawyers up, accuses Devoy of bullying, defamation
- Where polls stand on the eve of the first US presidential debate
- Former Fonterra director gives new governance proposal the thumbs up
- John Key: I won't take a traditional role after being PM
- Affco tried to gag union badmouthing Talleys as condition of meat contract talks
Most listened to
- Knewe Biosystems founder Dr Graeme Coles discusses the future of his product
- Media Snapchat: NBR’s Nick Grant ponders the Human Rights Commission’s role in RHOAKL racism row
- Craigs' Mark Lister on good equities returns for the September quarter to date
- 'It had become far too complicated so we threw it all out the window' – Jane Wrightson on NZOA's new funding model
- Matthew Hooton's picks for Key's next cabinet